OUR drug appears to be a stand-alone platform drug.... that would have trouble separating itself from something better known/advertised once comingled. Big Pharma would be making claims of efficacy from their perspective...and minimizing any claims to efficacy on our part...WE would definitely end up with...second banana...position...A mono-therapeutic position will give us the ammunition to move forward...then we'll be the Prom Queen...with multiple offers.